ClinicalTrials.gg
CompletedNCT00730691Updated Dec 18, 2013Results posted

Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

A Phase 3 interventional study of Placebo and Vortioxetine in Generalized Anxiety Disorder, sponsored by Takeda. Completed at 66 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
781
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
8th of 234
781 · median 90
Started
2008
with 19 others
Phase 3
45 of 265
6 open now
Registered
64th of 265
by date

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 8th largest by enrollment of the 234 interventional ones that give a count, is one of 20 that started in 2008, is one of 45 in phase 3, and was the 64th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.

Read the detailed description

Participants in this study will be randomly assigned to receive either 2.5 mg, 5 mg or 10 mg of vortioxetine, once daily, 60 mg of duloxetine once daily, or a placebo once daily for eight weeks.

Participants will be seen weekly during the first 2 weeks of treatment, and then every 2 weeks up to the end of the 8-week treatment period. Participants who complete the 8-week treatment period will enter a 2-week discontinuation period in order to assess potential discontinuation symptoms. Total commitment time is up to 12 weeks.

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Generalized Anxiety Disorder
  • Mood Disorder
  • Affective Disorder
  • Anxiety Disorder
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a primary diagnosis of generalized anxiety disorder according to the , Fourth Edition, Text Revision (DSM-IV-TR®) criteria (classification code 300.02).
  • Has a Hamilton Anxiety Scale total score ≥ 20. Has a Hamilton Anxiety Scale score ≥2 on both item 1 (anxious mood) and item 2 (tension).
  • Has a Montgomery-Åsberg Depression Rating Scale total score ≤16.

Exclusion criteria

Exclusion Criteria:

  • Had received any compound \<30 days before Screening or 5 half-lives prior to Screening, whichever is longer.
  • Received Lu AA21004 in a previous clinical study.
  • Was a study site employee, or an immediate family member (ie, spouse, parent, child, or sibling) of a study site employee involved in conduct of this study.
  • Has 1 or more of the following:

    • Any current psychiatric disorder other than Generalized Anxiety Disorder as defined in the ® (as assessed by the Mini International Neuropsychiatric Interview [MINI]).
    • Current or past history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR® and must have a negative urine drug screen prior to Baseline.
    • Presence or history of a neurological disorder (including epilepsy).
    • Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
    • Any Axis II disorder that might compromise the study.
  • Has known sensitivity to duloxetine.
  • Is taking excluded medications
  • Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on item 10 (suicidal thoughts) of the Montgomery-Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.
  • Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitor and/or serotonin-norepinephrine reuptake inhibitors.
  • Has received electroconvulsive therapy within 6 months prior to Screening.
  • Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
  • Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.
  • Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.
  • Has an , aspartate aminotransferase, or total level >1.5 times the .
  • Has a serum creatinine level >1.5 upper limit of normal.
  • Has a previous history of cancer that had been in remission for less than 5 years.
  • Hasclinically significant abnormal vital signs as determined by the investigator.
  • Has a history of lack of response to previous adequate treatment with duloxetine for any Generalized Anxiety Disorder episode.
  • Has 1 or more laboratory values outside the normal range, based on the blood or urine samples taken at the Screening Visit
  • Has a thyroid stimulating hormone value outside the normal range.
  • Has an abnormal .
  • has a disease or was taking medications that, in the opinion of the investigator, could have interfered with the assessments of safety, tolerability, or efficacy.
  • The patient, in the opinion of the investigator, was unlikely to comply with the clinical study protocol or was unsuitable for any reason.
  • Had previously been enrolled in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
781 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo-matching capsules, orally, once daily for up to 9 weeks.

    Drug: Placebo

  • Experimental
    Vortioxetine 2.5 mg

    Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.

    Drug: Placebo · Drug: Vortioxetine

  • Experimental
    Vortioxetine 5 mg

    Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.

    Drug: Placebo · Drug: Vortioxetine

  • Experimental
    Vortioxetine 10 mg

    Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.

    Drug: Placebo · Drug: Vortioxetine

  • Active comparator
    Duloxetine 60 mg

    Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.

    Drug: Duloxetine

Interventions

  • DrugPlacebo

    Placebo-matching capsules

  • Encapsulated vortioxetine immediate release tablets

    Also known as: Lu AA21004, Brintellix®

  • Overencapsulated duloxetine capsules

    Also known as: Cymbalta

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8

    The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Week 8

  2. Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 8

    The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the investigator relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Week 8

  3. Change From Baseline in Sheehan Disability Scale (SDS) at Week 8

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Week 8

  4. Percentage of Responders in HAM-A Total Score at Week 8

    Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Week 8

  5. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Week 8

  6. Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Weeks 1, 2, 4 and 6

  7. Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Other Weeks Assessed

    The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Weeks 1 and 4

  8. Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Other Weeks Assessed

    The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Weeks 1, 2, 4 and 6

  9. Change From Baseline in Sheehan Disability Scale (SDS) at Other Weeks Assessed

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Weeks 1, 2 and 4

  10. Percentage of Responders in HAM-A Total Score at Other Weeks Assessed

    Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Baseline and Weeks 1, 2, 4 and 6

  11. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to weeks 1, 2, 4 and 6

  12. Percentage of Participants in HAM-A Remission at Each Week Assessed

    Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Weeks 1, 2, 4, 6 and 8

  13. Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)

    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Weeks 1, 2, 4, 6 and 8

  14. Change From Baseline in Hospital Anxiety and Depression (HAD) - Depression Subscale at All Weeks Assessed

    The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) model with week, Baseline score-by-week and treatment-by-week interaction as factors.

    Time frame: Baseline to Weeks 1, 4 and 8

  15. Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire

    Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

    Time frame: Baseline and Week 8

07

Results

Posted Dec 18, 2013

Participant flow

Participants took part in the study at 71 investigative sites in the United States from 20 June 2008 to 27 February 2009.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Started157156156156156
Completed121120117111106
Not completed3636394550
Withdrew: Adverse event48111123
Withdrew: Lack of efficacy44211
Withdrew: Non-compliance with study drug61633
Withdrew: Protocol deviations35375
Withdrew: Withdrawal of consent79363
Withdrew: Lost to follow-up118131513
Withdrew: Other11122

Outcome measures

PrimaryChange From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8-11.27 ± 0.595-12.23 ± 0.600-11.57 ± 0.606-11.66 ± 0.606-13.87 ± 0.635
Statistical analysis
  • Placebo vs Vortioxetine 2.5 mg · Mixed model for repeated measurements · p = 0.255 (This treatment arm is not in the pre-specified testing sequence, a nominal p-value is provided.) · Ls mean difference: -0.96 · 95% CI -2.62 to 0.69P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.719 (Pre-specified sequential statistical testing procedure indicates that when p-value \>0.025, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.) · Ls mean difference: -0.30 · 95% CI -1.96 to 1.35P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = 0.642 (Pre-specified sequential statistical testing procedure indicates that when p-value \>0.025, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.) · Ls mean difference: -0.39 · 95% CI -2.06 to 1.27P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Duloxetine 60 mg · Mixed model for repeated measurements · p = 0.003 · Ls mean difference: -2.60 · 95% CI -4.30 to -0.89P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
SecondaryChange From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8

The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8-4.00 ± 0.361-3.89 ± 0.364-4.24 ± 0.366-5.09 ± 0.372-5.54 ± 0.385
Statistical analysis
  • Placebo vs Vortioxetine 2.5 mg · Mixed model for repeated measurements · p = 0.830 · Ls mean difference: 0.11 · 95% CI -0.89 to 1.11P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.643 (Hierarchical testing stopped at the primary endpoint in the testing sequence, a nominal p-value is provided.) · Ls mean difference: -0.24 · 95% CI -1.24 to 0.77P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = 0.036 (Hierarchical testing stopped at the primary endpoint in the testing sequence, a nominal p-value is provided.) · Ls mean difference: -1.09 · 95% CI -2.10 to -0.07P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Duloxetine 60 mg · Mixed model for repeated measurements · p = 0.004 · Ls mean difference: -1.54 · 95% CI -2.58 to -0.50P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
SecondaryMean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 8

The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the investigator relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 8
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 82.47 ± 0.0912.36 ± 0.0922.38 ± 0.0932.38 ± 0.0932.03 ± 0.098
Statistical analysis
  • Placebo vs Vortioxetine 2.5 mg · Mixed model for repeated measurements · p = 0.407 · Ls mean difference: -0.11 · 95% CI -0.36 to 0.15P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.533 · Ls mean difference: -0.08 · 95% CI -0.33 to 0.17P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = 0.491 · Ls mean difference: -0.09 · 95% CI -0.34 to 0.17P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Duloxetine 60 mg · Mixed model for repeated measurements · p = 0.001 · Ls mean difference: -0.44 · 95% CI -0.70 to -0.17P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) at Week 8

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) at Week 8
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Change From Baseline in Sheehan Disability Scale (SDS) at Week 8-6.35 ± 0.631-6.15 ± 0.647-6.68 ± 0.642-7.95 ± 0.623-8.81 ± 0.675
Statistical analysis
  • Placebo vs Vortioxetine 2.5 mg · Mixed model for repeated measurements · p = 0.652 · Ls mean difference: 0.35 · 95% CI -1.16 to 1.85P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.511 · Ls mean difference: -0.50 · 95% CI -1.98 to 0.98P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = 0.204 · Ls mean difference: -0.94 · 95% CI -2.38 to 0.51P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Duloxetine 60 mg · Mixed model for repeated measurements · p = 0.001 · Ls mean difference: -2.57 · 95% CI -4.10 to -1.03P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
SecondaryPercentage of Responders in HAM-A Total Score at Week 8

Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-A Total Score at Week 8
percentage of participantsPlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Percentage of Responders in HAM-A Total Score at Week 842.244.842.644.851.0
Statistical analysis
  • Placebo vs Vortioxetine 2.5 mg · Regression, Logistic · p = 0.641 · Odds ratio (or): 1.114 · 95% CI 0.709 to 1.750Logistic regression with explanatory variables for treatment and Baseline HAM-A score.
  • Placebo vs Vortioxetine 5 mg · Regression, Logistic · p = 0.945 · Odds ratio (or): 1.016 · 95% CI 0.643 to 1.605Logistic regression with explanatory variables for treatment and Baseline HAM-A score.
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.641 · Odds ratio (or): 1.114 · 95% CI 0.709 to 1.749Logistic regression with explanatory variables for treatment and Baseline HAM-A score.
  • Placebo vs Duloxetine 60 mg · Regression, Logistic · p = 0.124 · Odds ratio (or): 1.427 · 95% CI 0.907 to 2.246Logistic regression with explanatory variables for treatment and Baseline HAM-A score.
SecondaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25-11.61 ± 1.008-14.12 ± 0.945-13.87 ± 0.955-13.22 ± 0.999-16.15 ± 1.039
Statistical analysis
  • Placebo vs Vortioxetine 2.5 mg · Mixed model for repeated measurements · p = 0.064 · Ls mean difference: -2.50 · 95% CI -5.15 to 0.14P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.096 · Ls mean difference: -2.26 · 95% CI -4.92 to 0.40P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Vortioxetine 10 mg · Mixed model for repeated measurements · p = 0.250 · Ls mean difference: -1.61 · 95% CI -4.36 to 1.14P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
  • Placebo vs Duloxetine 60 mg · Mixed model for repeated measurements · p = 0.002 · Ls mean difference: -4.54 · 95% CI -7.34 to -1.73P-values are from an MMRM model with week, Baseline score-by-week and treatment-by-week interaction as factors.
SecondaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Week 1 (n= 151, 149, 142, 149, 143)-4.70 ± 0.423-4.56 ± 0.421-4.90 ± 0.430-5.04 ± 0.419-5.48 ± 0.435
Week 2 (n=147, 145, 143, 147, 130)-7.30 ± 0.472-7.28 ± 0.471-8.22 ± 0.476-7.63 ± 0.468-9.29 ± 0.494
Week 4 (n= 139, 135, 132, 133, 116)-8.66 ± 0.518-9.77 ± 0.520-9.84 ± 0.525-9.73 ± 0.519-11.13 ± 0.553
Week 6 (n= 127, 123, 122, 120, 112)-10.28 ± 0.547-10.82 ± 0.553-11.26 ± 0.556-11.05 ± 0.552-12.66 ± 0.583
SecondaryChange From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Other Weeks Assessed

The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Weeks 1 and 4
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Week 1 (n=150, 149, 141, 149, 141)-1.81 ± 0.273-1.85 ± 0.274-1.89 ± 0.280-2.22 ± 0.272-2.91 ± 0.285
Week 4 (n=141, 142, 139, 141, 126)-3.24 ± 0.310-3.34 ± 0.310-3.60 ± 0.313-4.01 ± 0.310-5.11 ± 0.328
SecondaryMean Clinical Global Impression Scale-Global Improvement (CGI-I) at Other Weeks Assessed

The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Week 1 (n=151, 148, 141, 149, 141)3.44 ± 0.0673.46 ± 0.0683.41 ± 0.0693.40 ± 0.0673.36 ± 0.070
Week 2 (n=147, 145, 142, 147, 129)3.03 ± 0.0723.08 ± 0.0722.90 ± 0.0732.96 ± 0.0722.76 ± 0.077
Week 4 (n=140, 135, 132, 134, 116)2.81 ± 0.0792.67 ± 0.0802.67 ± 0.0812.68 ± 0.0802.44 ± 0.085
Week 6 (n=127, 123, 121, 120, 112)2.61 ± 0.0822.53 ± 0.0832.43 ± 0.0842.41 ± 0.0832.25 ± 0.088
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) at Other Weeks Assessed

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Weeks 1, 2 and 4
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Week 1 (n=116, 111, 109, 125, 112)-3.22 ± 0.506-2.74 ± 0.521-3.28 ± 0.521-4.11 ± 0.483-4.74 ± 0.521
Week 2 (n=116, 114, 116, 123, 103)-4.53 ± 0.536-4.18 ± 0.547-5.02 ± 0.542-5.46 ± 0.514-7.09 ± 0.563
Week 4 (n=108, 106, 106, 115, 91)-4.55 ± 0.590-4.98 ± 0.604-5.92 ± 0.600-6.47 ± 0.568-7.95 ± 0.632
SecondaryPercentage of Responders in HAM-A Total Score at Other Weeks Assessed

Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Baseline and Weeks 1, 2, 4 and 6
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-A Total Score at Other Weeks Assessed
percentage of participantsPlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Week 1 (n=151, 149, 142, 149, 143)11.36.78.510.116.8
Week 2 (n=154, 154, 147, 154, 149)20.820.121.121.428.9
Week 4 (n=154, 154, 148, 154, 149)26.030.532.435.142.3
Week 6 (n=154, 154, 148, 154, 149)36.437.740.540.947.7
SecondaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Week 1 (n=63, 76, 70, 70, 66)-5.32 ± 0.787-6.07 ± 0.719-5.96 ± 0.749-5.94 ± 0.740-6.78 ± 0.770
Week 2 (n=62, 73, 70, 68, 62)-7.55 ± 0.856-8.82 ± 0.785-10.18 ± 0.810-8.51 ± 0.808-10.40 ± 0.844
Week 4 (n=60, 68, 67, 63, 54)-8.61 ± 0.901-11.61 ± 0.837-12.87 ± 0.854-10.98 ± 0.862-12.56 ± 0.914
Week 6 (n=58, 63, 62, 54, 51)-10.72 ± 0.937-12.86 ± 0.880-14.11 ± 0.895-12.75 ± 0.918-14.35 ± 0.961
SecondaryPercentage of Participants in HAM-A Remission at Each Week Assessed

Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Weeks 1, 2, 4, 6 and 8
Reported as:
Number · percentage of participants
Percentage of Participants in HAM-A Remission at Each Week Assessed
percentage of participantsPlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Week 1 (n=151, 149, 142, 149, 143)4.02.00.72.04.9
Week 2 (n=154, 154, 147, 154, 149)6.58.47.53.912.1
Week 4 (n=154, 154, 148, 154, 149)10.413.611.513.017.4
Week 6 (n=154, 154, 148, 154, 149)16.214.914.916.920.8
Week 8 (n=154, 154, 148, 154, 149)22.120.119.620.128.2
SecondaryChange From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Weeks 1, 2, 4, 6 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Week 1 (n=151, 148, 141, 149, 142)-0.42 ± 0.055-0.37 ± 0.055-0.39 ± 0.056-0.42 ± 0.054-0.54 ± 0.057
Week 2 (n=147, 145, 142, 147, 130)-0.71 ± 0.066-0.74 ± 0.066-0.80 ± 0.067-0.75 ± 0.065-0.97 ± 0.069
Week 4 (n=140, 135, 132, 134, 115)-0.95 ± 0.076-1.12 ± 0.077-1.02 ± 0.077-1.11 ± 0.076-1.28 ± 0.082
Week 6 (n=127, 123, 121, 120, 112)-1.22 ± 0.083-1.32 ± 0.084-1.31 ± 0.084-1.35 ± 0.084-1.55 ± 0.088
Week 8 (n=120, 118, 114, 111, 106)-1.42 ± 0.095-1.50 ± 0.096-1.38 ± 0.097-1.44 ± 0.097-1.77 ± 0.101
SecondaryChange From Baseline in Hospital Anxiety and Depression (HAD) - Depression Subscale at All Weeks Assessed

The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) model with week, Baseline score-by-week and treatment-by-week interaction as factors.

Time frame:
Baseline to Weeks 1, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Hospital Anxiety and Depression (HAD) - Depression Subscale at All Weeks Assessed
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Week 1 (n=150, 149, 141, 149, 141)-0.81 ± 0.226-0.83 ± 0.226-0.88 ± 0.231-1.25 ± 0.225-1.19 ± 0.235
Week 4 (n=141, 142, 139, 141, 126)-1.32 ± 0.268-1.83 ± 0.268-1.70 ± 0.271-1.61 ± 0.268-2.62 ± 0.283
Week 8 (n=123, 120, 119, 111, 108)-2.21 ± 0.300-1.82 ± 0.303-1.96 ± 0.305-1.94 ± 0.310-2.77 ± 0.320
SecondaryHealth Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire

Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
participantsPlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Baseline: Any resource use3436264338
Baseline: Any hospitalization-related services03102
Baseline: Hospitalization related to anxiety02100
Baseline: Any sick leave1416131512
Baseline: Sick leave related to anxiety510997
Week 8: Any resource use2624292322
Week 8: Any hospitalization-related service00013
Week 8: Hospitalization related to anxiety00001
Week 8: Any sick leave1367711
Week 8: Sick leave related to anxiety22314

Adverse events

Collected over From the first dose of double-blind study medication through 30 days after permanent discontinuation of double-blind study medication.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/155 (0%)85/155 (54.8%)
Vortioxetine 2.5 mg—1/156 (0.6%)100/156 (64.1%)
Vortioxetine 5 mg—0/155 (0%)104/155 (67.1%)
Vortioxetine 10 mg—1/156 (0.6%)111/156 (71.2%)
Duloxetine 60 mg—3/154 (1.9%)116/154 (75.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
Angina pectorisCardiac disorders0/1550/1560/1550/1561/154
SomnolenceNervous system disorders0/1550/1560/1550/1561/154
Sexual abuseSocial circumstances0/1550/1560/1550/1561/154
Abdominal herniaGastrointestinal disorders0/1550/1560/1551/1560/154
Benign prostatic hyperplasiaReproductive system and breast disorders0/1551/1560/1550/1560/154
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mg
NauseaGastrointestinal disorders27/15526/15645/15553/15657/154
HeadacheNervous system disorders20/15518/15620/15525/15626/154
Dry mouthGastrointestinal disorders10/15514/15617/15521/15625/154
DiarrhoeaGastrointestinal disorders9/1559/15611/15520/1566/154
SomnolenceNervous system disorders6/1557/15613/1558/15618/154
DizzinessNervous system disorders5/15513/1569/15514/15617/154
FatigueGeneral disorders3/1556/1568/1559/15615/154
NasopharyngitisInfections and infestations7/15514/1567/15512/1563/154
ConstipationGastrointestinal disorders6/15510/1564/15512/1568/154
Upper respiratory tract infectionInfections and infestations9/15512/15611/15512/1568/154

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mgTotal
Mean36.8 ± 12.1239.2 ± 11.9037.7 ± 11.9639.8 ± 12.3339.5 ± 12.2838.6 ± 12.14
Age, Customized
Age, Customized(participants)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mgTotal
≤55 years143140147137137704
>55 years14169191977
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mgTotal
Female102109100105113529
Male5547565143252
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mgTotal
Caucasian (White, including Hispanic)118121124120121604
Black3531263331156
Asian4060414
American Indian or Alaska Native010203
Native Hawaiian/ Other Pacific Islander010102
Region of Enrollment
Region of Enrollment(participants)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mgTotal
United States157156156156156781
Weight
Weight(kg)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mgTotal
Mean84.40 ± 25.42679.47 ± 19.89380.98 ± 20.31280.17 ± 21.42079.51 ± 20.09080.91 ± 21.558
Height
Height(cm)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mgTotal
Mean168.74 ± 9.605167.87 ± 9.139169.25 ± 9.282167.61 ± 8.378167.94 ± 9.300168.28 ± 9.147
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgVortioxetine 10 mgDuloxetine 60 mgTotal
Mean29.54 ± 8.47828.19 ± 6.65128.24 ± 6.58928.49 ± 7.05828.10 ± 6.32528.51 ± 7.064

7 further baseline measures are reported on the registry.

08

Study locations

66 sites
  • Anaheim, California, United States
  • Beverly Hills, California, United States
  • Fresno, California, United States
  • Los Angeles, California, United States
  • Oceanside, California, United States
  • San Diego, California, United States
  • Sherman Oaks, California, United States
  • Widomar, California, United States
  • Denver, Colorado, United States
  • Farmington, Connecticut, United States
  • Norwalk, Connecticut, United States
  • Coral Gables, Florida, United States
  • Jacksonville, Florida, United States
  • Maitland, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • West Palm Beach, Florida, United States
  • Winter Park, Florida, United States
  • Atlanta, Georgia, United States
  • Roswell, Georgia, United States
  • Smyrna, Georgia, United States
  • Honolulu, Hawaii, United States
  • Oakbrook Ter, Illinois, United States
  • Terre Haute, Indiana, United States
  • Owensboro, Kentucky, United States
  • Shreveport, Louisiana, United States
  • Rockville, Maryland, United States
  • Chesterfield, Missouri, United States
  • St Louis, Missouri, United States
  • Nashua, New Hampshire, United States
  • Clementon, New Jersey, United States
  • Princeton, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Brooklyn, New York, United States
  • Cedarhurst, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Staten Island, New York, United States
  • Charlotte, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Beachwood, Ohio, United States
  • Cleveland, Ohio, United States
  • Dayton, Ohio, United States
  • Toledo, Ohio, United States
  • Eugene, Oregon, United States
  • Portland, Oregon, United States
  • Salem, Oregon, United States
  • Allentown, Pennsylvania, United States
  • Media, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Columbia, South Carolina, United States
  • Memphis, Tennessee, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • DeSoto, Texas, United States
  • Houston, Texas, United States
  • Lake Jackson, Texas, United States
  • Wichita Falls, Texas, United States
  • Midvale, Utah, United States
  • Woodstock, Vermont, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Brown Deer, Wisconsin, United States
  • Middleton, Wisconsin, United States
  • Milwaukee, Wisconsin, United States
09

References and documents

Publications

  • Mahableshwarkar AR, Jacobsen PL, Chen Y, Simon JS. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract. 2014 Jan;68(1):49-59. doi: 10.1111/ijcp.12328. PubMed 24341301 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2008
First posted
Aug 8, 2008
Start
Jun 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Dec 18, 2013
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00730691
Lead sponsor
Takeda
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Aug 8, 2008
Start date
Jun 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Dec 18, 2013
Last update
Dec 18, 2013

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion